Annexon Biosciences Is A Clinical Stage Biopharmaceutical Company Listed On The Nasdaq Under The Ticker Symbol Annxthe Company Specializes In Developing Novel Therapeutics That Target C1Qa Key Molecule In The Classical Complement Pathwayto Treat Autoimmuneneurodegenerativeand Ophthalmic Diseasesthis Unique Focus On C1Q Inhibition Sets Annexon Apart In The Biopharmaceutical Industry The Company S Pipeline Includes Promising Candidates Such As Anx007Which Has Shown Significant Preservation Of Visual Function In Patients With Geographic Atrophy During A Phase 2 Trialand Anx1502Which Met Pharmacokinetic Targets In A Phase 1 Studyannexon Is Committed To Improving Patient Outcomes For Those Suffering From Complement Mediated Diseasesreflecting Its Dedication To Delivering Transformative Therapiesthe Leadership Team Brings Extensive Experience In Biotechnologyenhancing The Company S Potential For Success In The Sector
